Wang Yaobang, Wang Xi, Huang Xiaoliang, Zhang Jie, Hu Junwen, Qi Yapeng, Xiang Bangde, Wang Qiuyan
Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
J Cancer. 2021 Mar 19;12(10):2993-3010. doi: 10.7150/jca.56005. eCollection 2021.
Dual-phenotype hepatocellular carcinoma (DPHCC) expresses both hepatocyte and cholangiocyte markers, and is characterized by high recurrence and low survival rates. The underlying molecular mechanisms of DPHCC pathogenesis are unclear. We performed whole exome sequencing and RNA sequencing of three subtypes of HCC (10 DPHCC, 10 CK19-positive HCC, and 14 CK19-negative HCC), followed by integrated bioinformatics analysis, including somatic mutation analysis, mutation signal analysis, differential gene expression analysis, and pathway enrichment analysis. Cox proportional hazard regression analyses were applied for exploring survival related characteristics. We found that mutated genes in DPHCC patients were associated with carcinogenesis and immunity, and the up-regulated genes were mainly enriched in transcription-related and cancer-related pathways, and the down-regulated genes were mainly enriched in immune-related pathways. CXCL9 was selected as the hub gene, which is associated with immune cells and survival prognosis. Our results showed that low CXCL9 expression was significantly associated with poor prognosis, and its expression was significantly reduced in DPHCC samples. In conclusion, we explored the molecular mechanisms governing DPHCC development and progression and identified CXCL9, which influences the immune microenvironment and prognosis of DPHCC and might be new clinically significant biomarkers for predicting prognosis.
双表型肝细胞癌(DPHCC)同时表达肝细胞和胆管细胞标志物,其特点是高复发率和低生存率。DPHCC发病机制的潜在分子机制尚不清楚。我们对三种肝癌亚型(10例DPHCC、10例CK19阳性肝癌和14例CK19阴性肝癌)进行了全外显子组测序和RNA测序,随后进行了综合生物信息学分析,包括体细胞突变分析、突变信号分析、差异基因表达分析和通路富集分析。应用Cox比例风险回归分析来探索生存相关特征。我们发现DPHCC患者的突变基因与致癌作用和免疫相关,上调基因主要富集在转录相关和癌症相关通路,下调基因主要富集在免疫相关通路。选择CXCL9作为枢纽基因,其与免疫细胞和生存预后相关。我们的结果表明,CXCL9低表达与预后不良显著相关,且其在DPHCC样本中的表达显著降低。总之,我们探索了DPHCC发生发展的分子机制,并鉴定出CXCL9,其影响DPHCC的免疫微环境和预后,可能是预测预后的新的具有临床意义的生物标志物。